As cells deficient in BRCA1/2 cannot repair DSBs, they are particularly sensitive to the effects of PARP inhibition, resulting in synthetic lethality in tumor cells carrying the mutation while normal cells are spared [5]. The gene discussed is BRCA1; the disease is neoplasm.